J. G. Montoya, O. Liesenfeld, and . Toxoplasmosis, Lancet Lond Engl. 12 juin, vol.363, issue.9425, pp.1965-76, 2004.

L. M. Weiss and J. P. Dubey, Toxoplasmosis: A history of clinical observations, Int J Parasitol. 1 juill, vol.39, issue.8, pp.895-901, 2009.

F. Robert-gangneux and M. Darde, Epidemiology of and Diagnostic Strategies for Toxoplasmosis, Clin Microbiol Rev. 1 avr, vol.25, issue.2, pp.264-96, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00696903

G. Pappas, N. Roussos, and M. E. Falagas, Toxoplasmosis snapshots: Global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis, Int J Parasitol, vol.39, issue.12, pp.1385-94, 2009.

J. Flegr, J. Prandota, M. Sovi?ková, and Z. H. Israili, Toxoplasmosis -A Global Threat. Correlation of Latent Toxoplasmosis with Specific Disease Burden in a Set of 88 Countries, Disponible sur, vol.9

, Statista, 2017.

D. Sur,

C. A. Mccannel, G. N. Holland, C. J. Helm, P. J. Cornell, J. V. Winston et al., Causes of Uveitis in the General Practice of Ophthalmology, Am J Ophthalmol. 1 janv, vol.121, issue.1, pp.35-46, 1996.

A. A. Bonfioli, F. Orefice, and . Toxoplasmosis, Semin Ophthalmol. 1 janv, vol.20, issue.3, pp.129-170, 2005.

A. Rothova, J. H. De-boer, T. Dam-van-loon, N. H. Postma, G. De-visser et al., Usefulness of aqueous humor analysis for the diagnosis of posterior uveitis, Ophthalmology. févr, vol.115, issue.2, pp.306-317, 2008.

J. G. Garweg, J. De-groot-mijnes, and J. G. Montoya, Diagnostic approach to ocular toxoplasmosis, Ocul Immunol Inflamm. août, vol.19, issue.4, pp.255-61, 2011.

O. Villard, D. Filisetti, F. Roch-deries, J. Garweg, J. Flament et al., Comparison of enzyme-linked immunosorbent assay, immunoblotting, and PCR for diagnosis of toxoplasmic chorioretinitis, J Clin Microbiol. août, vol.41, issue.8, pp.3537-3578, 2003.

C. Ozgonul and C. G. Besirli, Recent Developments in the Diagnosis and Treatment of Ocular Toxoplasmosis, Ophthalmic Res, vol.57, issue.1, pp.1-12, 2017.

C. T. Friedmann and D. L. Knox, Variations in Recurrent Active Toxoplasmic Retinochoroiditis, Arch Ophthalmol. 1 avr, vol.81, issue.4, pp.481-93, 1969.

M. Reich, M. Ruppenstein, M. D. Becker, and F. Mackensen, Time patterns of recurrences and factors predisposing for a higher risk of recurrence of ocular toxoplasmosis, Retina Phila Pa. avr, vol.35, issue.4, pp.809-828, 2015.

G. N. Holland, A Controlled Retrospective Study of Ganciclovir Treatment for Cytomegalovirus Retinopathy: Use of a Standardized System for the Assessment of Disease Outcome, Arch Ophthalmol. 1 déc, vol.107, issue.12, p.1759, 1989.

A. F. Lasave, M. Díaz-llopis, C. Muccioli, R. Belfort, and J. F. Arevalo, Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months, Ophthalmology. sept, vol.117, issue.9, pp.1831-1839, 2010.

D. Eyles, C. N. Eyles, D. E. , and C. N. , Antibiotics in the treatment of toxoplasmosis, Am J Trop Med Hyg, vol.2, pp.64-73, 1953.

E. M. Opremcak, D. K. Scales, and M. R. Sharpe, Trimethoprim-sulfamethoxazole therapy for ocular toxoplasmosis, Ophthalmology. juin, vol.99, issue.6, pp.920-925, 1992.

N. J. Butler, J. M. Furtado, K. L. Winthrop, J. Smith, L. H. Bosch-driessen et al., Ocular toxoplasmosis II: clinical features, pathology and management, Clin Experiment Ophthalmol. févr, vol.41, issue.1, pp.95-108, 2013.

C. B. Hoyng, A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis, Am J Ophthalmol. 1 juill, vol.134, issue.1, pp.34-40, 2002.

M. Soheilian, A. Ramezani, A. Azimzadeh, M. M. Sadoughi, M. H. Dehghan et al., Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis, Ophthalmology. janv, vol.118, issue.1, pp.134-175, 2011.

C. Silveira, R. Belfort, C. Muccioli, G. N. Holland, C. G. Victora et al., The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis, Am J Ophthalmol. juill, vol.134, issue.1, pp.41-47, 2002.

J. G. Montoya and J. S. Remington, Management of Toxoplasma gondii infection during pregnancy, Clin Infect Dis Off Publ Infect Dis Soc Am. 15 août, vol.47, issue.4, pp.554-66, 2008.

R. R. Ben-harari, E. Goodwin, and J. Casoy, Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review, Drugs RD. déc, vol.17, issue.4, pp.523-567, 2017.

G. Choquet-kastylevsky, T. Vial, and J. Descotes, Allergic adverse reactions to sulfonamides, Curr Allergy Asthma Rep. janv, vol.2, issue.1, pp.16-25, 2002.

D. Cam, A. O. Saatci, S. C. Micili, B. U. Ergur, R. Y. Karabag et al., The Effect of Intravitreal Azithromycin on the Albino Newborn Rabbit Retina, Open Ophthalmol J, vol.10, pp.12-18, 2016.

C. Canamucio, W. Hallet, and L. J. , Recurrence of treated toxoplasmic uveitis, Am J Ophthalmol, issue.55, pp.1035-1044, 1963.

A. Rothova, L. Bosch-driessen, N. H. Loon, . Van, and W. F. Treffers, Azithromycin for ocular toxoplasmosis, Br J Ophthalmol, vol.82, issue.11, pp.1306-1314, 1998.

V. Lakhanpal, S. S. Schocket, and V. S. Nirankari, Clindamycin in the treatment of toxoplasmic retinochoroiditis, Am J Ophthalmol. mai, vol.95, issue.5, pp.605-618, 1983.

Z. Benzina, S. Chaabouni, N. Hentati, A. Trigui, F. Chaabouni et al., Récurrence de la rétinochoroïdite toxoplasmique après traitement par clindamycine, J Fr D39Ophtalmologie, vol.28, issue.9, pp.958-64

J. Huskinson-mark, F. G. Araujo, and J. S. Remington, Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii, J Infect Dis. juill, vol.164, issue.1, pp.170-171, 1991.

J. Colin and J. Harie, Choriorétinites présumées toxoplasmiques étude : comparative des traitements par pyriméthamine et sulfadiazine ou clindamycine, J Fr Ophtalmol, vol.3, pp.161-166, 1989.

Y. F. Zamora, T. Arantes, F. A. Reis, C. R. Garcia, J. Saraceno et al., Local treatment of toxoplasmic retinochoroiditis with intravitreal clindamycin and dexamethasone, Arq Bras Oftalmol. août, vol.78, issue.4, pp.216-225, 2015.

C. E. Martinez, D. Zhang, M. D. Conway, and G. A. Peyman, Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine, Int Ophthalmol, vol.22, issue.2, pp.85-93, 19991998.

Z. Habot-wilner, O. Mazza, J. Shahar, A. Massarweh, I. Mann et al., Safety of intravitreal clindamycin in albino rabbit eyes, Doc Ophthalmol, vol.135, issue.2, pp.133-179, 2017.

, Ocular safety of Intravitreal Clindamycin Hydrochloride Released by PLGA Implants, Pharm Res, vol.34, issue.5, pp.1083-92, 2017.

E. R. Pfefferkorn, R. F. Nothnagel, and S. E. Borotz, Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant, Antimicrob Agents Chemother. mai, vol.36, issue.5, pp.1091-1097, 1992.

K. Kishore, M. D. Conway, and G. A. Peyman, Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis, Ophthalmic Surg Lasers. juin, vol.32, issue.3, pp.183-92, 2001.

M. Castillo, S. Gallego-pinazo, R. Francés-muñoz, E. Dolz-marco, R. et al., Toxoplasmosis macular y clindamicina intravítrea: una alternativa al tratamiento oral, Arch Soc Esp Oftalmol. 1 mars, vol.87, issue.3, pp.93-98, 2012.

L. Sobrin, L. I. Kump, and C. S. Foster, Intravitreal clindamycin for toxoplasmic retinochoroiditis, Retina Phila Pa. sept, vol.27, issue.7, pp.952-959, 2007.

. Bor'i-a, A. Mahrous, M. A. Al-aswad, A. , H. Y. Nada et al., Intravitreal Clindamycin and Dexamethasone Combined with Systemic Oral Antitoxoplasma Therapy versus Intravitreal Therapy Alone in the Management of Toxoplasma Retinochoroiditis: A Retrospective Study, Journal of Ophthalmology, vol.115, issue.4, pp.517-540, 1993.

, une diminution significative d'environ 2 diamètres papillaires a été constatée. La taille moyenne des différents foyers passant de 3,82 dp à 1,98dp

, Concernant l'épaisseur maculaire, on constate également une diminution significative, avec plus de 333µm (+/-89,9µ m) avant traitement vs 255(+/-76,5) à 6mois post IVT. Une réaugmentation secondaire de l'épaisseur maculaire à 6 mois est constatée dans 2 cas

, L'acuité visuelle est également améliorée lors des IVT de clindamycine, avec une AV initiale à environ 1 LogMAR (1,07 +/-0,77) pré injection, s'améliorant

, Les IVT de clindamycines se sont montrées sûres et efficaces pour le traitement des RCT. Avec une diminution de l'inflammation, de la taille du foyer et de l'épaisseur maculaire, une amélioration de la meilleure acuité visuelle à 6 mois

J. G. Montoya, O. Liesenfeld, and . Toxoplasmosis, Lancet. 12 juin, vol.363, issue.9425, pp.1965-76, 2004.

C. A. Mccannel, G. N. Holland, C. J. Helm, P. J. Cornell, J. V. Winston et al., Causes of Uveitis in the General Practice of Ophthalmology, American Journal of Ophthalmology. 1 janv, vol.121, issue.1, pp.35-46, 1996.

J. L. Jones, V. Dargelas, J. Roberts, C. Press, J. S. Remington et al., Risk factors for Toxoplasma gondii infection in the United States, Clin Infect Dis. 15 sept, vol.49, issue.6, pp.878-84, 2009.

A. G. Commodaro, R. N. Belfort, L. V. Rizzo, C. Muccioli, C. Silveira et al., Ocular toxoplasmosis: an update and review of the literature, Mem Inst Oswaldo Cruz, vol.104, issue.2, pp.345-50, 2009.

A. A. Bonfioli, F. Orefice, and . Toxoplasmosis, Seminars in Ophthalmology. 1 janv, vol.20, issue.3, pp.129-170, 2005.

A. Rothova, L. Bosch-driessen, N. H. Loon, . Van, and W. F. Treffers, Azithromycin for ocular toxoplasmosis, British Journal of Ophthalmology, vol.82, issue.11, pp.1306-1314, 1998.

L. H. Bosch-driessen, F. D. Verbraak, M. Suttorp-schulten, R. Van-ruyven, A. M. Klok et al., A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis, American Journal of Ophthalmology. 1 juill, vol.134, issue.1, pp.34-40, 2002.

B. Iaccheri, T. Fiore, T. Papadaki, S. Androudi, S. Janjua et al., Adverse drug reactions to treatments for ocular toxoplasmosis: a retrospective chart review, Clin Ther, vol.30, issue.11, pp.2069-74, 2008.

C. E. Martinez, D. Zhang, M. D. Conway, and G. A. Peyman, Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine, Int Ophthalmol, vol.22, issue.2, pp.85-93, 19991998.

K. Kishore, M. D. Conway, and G. A. Peyman, Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis, Ophthalmic Surg Lasers. juin, vol.32, issue.3, pp.183-92, 2001.

L. S-obrin, L. I. Kump, and C. S. Foster, Intravitreal clindamycin for toxoplasmic retinochoroiditis, Retina

G. N. Holland, A Controlled Retrospective Study of Ganciclovir Treatment for Cytomegalovirus Retinopathy: Use of a Standardized System for the Assessment of Disease Outcome, Arch Ophthalmol. 1 déc, vol.107, issue.12, p.1759, 1989.

A. F. Lasave, M. Díaz-llopis, C. Muccioli, R. Belfort, and J. F. Arevalo, Intravitreal Clindamycin and Dexamethasone for Zone 1 Toxoplasmic Retinochoroiditis at Twenty-four Months, Ophthalmology. 1 sept, vol.117, issue.9, pp.1831-1839, 2010.

M. Soheilian, A. Ramezani, A. Azimzadeh, M. M. Sadoughi, M. H. Dehghan et al., Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis, Ophthalmology. janv, vol.118, issue.1, pp.134-175, 2011.

A. Rothova, C. Meenken, H. J. Buitenhuis, C. J. Brinkman, G. S. Baarsma et al., Therapy for Ocular Toxoplasmosis, American Journal of Ophthalmology. 1 avr, vol.115, issue.4, pp.517-540, 1993.

. Bor'i-a, A. Mahrous, M. A. Al-aswad, A. , H. Y. Nada et al., Intravitreal Clindamycin and Dexamethasone Combined with Systemic Oral Antitoxoplasma Therapy versus Intravitreal Therapy Alone in the Management of Toxoplasma Retinochoroiditis: A Retrospective Study, Journal of Ophthalmology, 2018.

D. Sur,